Before today's Food and Drug Administration advisory committee voted unanimously, 12-0, in favor of NPS Pharmaceuticals, health care analysts David Williamson and Max Macaluso discussed the likelihood of FDA approval for its lead drug, Gattex. Although getting a positive vote out of the advisory committee it is just a step in overall approval, today is an important day for NPS and its shareholders.
Many investors are attracted to NPS and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
Dave Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.